Status:
RECRUITING
FMRI-neurofeedback in Parkinson's Disease
Lead Sponsor:
Maastricht University Medical Center
Conditions:
Parkinson Disease
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Rationale: Current treatment of patients with Parkinson's disease (PD) is mainly based on the modulation of neural activity in the motor circuits of the basal ganglia and cerebral cortex by either dru...
Detailed Description
Parkinson's disease (PD) is associated with progressive neurodegeneration of dopaminergic neurons of the substantia nigra. It is characterized by both motor and non-motor system manifestations. Dopami...
Eligibility Criteria
Inclusion
- Diagnosis of Parkinson's disease.
- Disease stage 1-3 according to the Hoehn and Yahr Scale
- Age: 18 years or more
Exclusion
- Exclusion criteria for MRI (e.g., cardiac pacemaker, certain metallic implants)
- History of psychotic disorder, bipolar disorder, or psychotic depression
- Current use of illegal drugs (any in the last four weeks)
- Current excessive alcohol consumption that interferes with daily functioning
- A score on the Montreal Cognitive Assessment (MoCA) below 24/30.
- Any disorder that would interfere with accurate and usable data acquisition.
Key Trial Info
Start Date :
February 10 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06582355
Start Date
February 10 2025
End Date
December 1 2026
Last Update
March 24 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Uniklinik Köln
Cologne, Germany
2
Maastricht University
Maastricht, Netherlands